Abstract
Successful stem cell mobilization and collection is possible in B-CLL after a favorable response to preceding chemotherapy, and also after treatment with the new nucleoside analogues fludarabine and cladribine. A poor response, on the other hand, seemed to predict a mobilization failure. CD34+ cell selection resulted in a 2- to 3-log reduction of the CLL cells in the harvests. Engraftment with both unselected and selected progenitor cells was rapid, and need for hospitalization was short. High-dose therapy with stem cell rescue appears to be capable of inducing CRs of high quality, but so far the follow-up is too short to define whether this will be translated into prolonged disease-free survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Itälä, M., Pelliniemi, TT., Rajamäki, A. et al. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 19, 647–651 (1997). https://doi.org/10.1038/sj.bmt.1700730
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/sj.bmt.1700730
Keywords
This article is cited by
-
Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis
Bone Marrow Transplantation (2008)
-
Transplantation in chronic lymphocytic leukemia
Current Hematologic Malignancy Reports (2007)
-
Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience
Bone Marrow Transplantation (2006)
-
Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment
Annals of Hematology (2005)
-
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Bone Marrow Transplantation (2002)


